RIQAS Point of Care EQA

Home - PT

RIQAS Point of Care EQA

RIQAS Point of Care EQA Logo

EQA Designed to Provide Peace of Mind at the Point of Care

Designed to improve the quality of Point of Care Testing (POCT) in locations such as pharmacies, GP surgeries, hospital out patient departments, sports clinics, supermarkets, diagnostic/treatment and walk-in centres.

RIQAS Point of Care EQA provides independent evidence of the accuracy and reliability of test results.

Why RIQAS Point of Care?

Programme Offering

Tests

Role

Matrix

Lipids (Total Cholesterol & HDL Cholesterol)*

  • Risk Factor for heart Disease
  • Monitoring lipid lowering therapy

Whole Blood

HbA1c (Glycated Hemoglobin)*

  • Diagnosing diabetes mellitus
  • Monitoring treatment
  • Encouraging self-management

Whole Blood

CRP (C Reactive Protein)*

  • Early detection of infectious disease
  • Identifying need for antibiotic treatment

Whole Blood

Glucose / Ketones

  • Diagnose and monitor diabetes
  • Monitor the presence of hypoglycemia (low blood glucose) and hyperglycemia (high blood glucose)
  • To determine whether excessive ketones are present in the blood, to detect diabetic ketoacidosis (DKA)

Serum

International Normalised Ratio (INR)

  • Used to measure the effect of anticoagulant drugs such as warfarin
  • Help diagnose a bleeding disorder; to help estimate the severity of liver disease

Whole Blood

  • Key Cycle Dates

    RQ9181
    Distribution Month Sample Distributed Result Submission Deadline
    January 2024 8th January 17th January
    February 2024 5th February 14th February
    March 2024 4th March 13th March
    April 2024 2nd April 10th April
    May 2024 6th  May 15th May
    June 2024 3rd June 12th June
    July 2024 1st  July 10th July
    August 2024 5th August 14th August
    September 2024 2nd September 11th September
    October 2024 7th October 16th October
    November 2024 4th November 13th November
    December 2024 2nd December 11th December
  • What Participants Say

    What participants say

    Our unrivalled commitment to quality and service ensures high levels of customer satisfaction, this is evident from the responses to our latest customer satisfaction survey:

    “All in all a quick and efficient service”

    “Good online system”

    “Very helpful team”

    “Excellent training”

    “They are an experienced team”

    “Very satisfied with the service that we receive”

    “Very good value for money”

    “The website is great”

  • The Importance of Quality Assurance

    Importance of quality assurance

    Quality assurance is an essential aspect of any clinical/diagnostic testing service and is aimed at ensuring the accuracy and reliability of patients’ results. The right result allows the right clinical advice to be offered in a timely manner. Quality assurance operates at two levels:Internal Quality Control

    Internal Quality Control includes operator training/ competency assessment, analyser/ test system maintenance, and adherence to policies/ processes. Whilst some point of care analysers include inbuilt quality checks, cross-check analysis against samples with known levels provides immediate assurance and evidence that a patient’s result is safe to report.External Quality Assessment

    External Quality Assessment involves analysis of samples with unknown levels that have been distributed by an external organisation. Participants are informed how their results compare with other participants, hence providing independent evidence of performance. Increasingly, participation in an external quality assessment scheme is becoming a mandatory requirement where health and healthcare services are being provided.

    EQA provides assurance to both staff and customers that testing provides accurate and reliable results.

Want to know more?

Contact us or download the RIQAS Point of Care catalogue to learn more.

Continue Reading

Frequently Asked Questions

RIQAS

Contact Us


Acusera 24.7 – Interlaboratory Data Management Reporting Software

Acusera 24•7 is a live, cloud based interlaboratory data management and peer group reporting software, intended to assist in the management of daily QC activities.

Designed to complement our range of Acusera true third party controls.

Key Benefits of Acusera 24•7

null

Peer Group Statistics

Updated live in real-time, labs can compare statistics to their peers and identify any unique or widespread issues to help reduce time and money spent on troubleshooting.

null

Fully Interactive Charts

Ability to compare performance, assess trends and monitor performance with automatically generated Levey-Jennings, Histograms and Performance Summary Charts.

null

Highly Flexible

Labs can configure their own performance limits, multi-rules, consensus groups and target values for each instrument or lot of QC.

null

Comprehensive Reports

Comprehensive, easy-to-read and customisable reports have been designed to speed up the review process and include Statistical Metrics, Uncertainty of Measurement, Exception & more.

null

24/7 Access

Gain access to this cloud-based software at anytime, anywhere. Removing the need installation, software maintenance and frequent back-ups.

null

Advanced Statistical Analysis

Automatically calculating advanced statistics including %Bias, Total Error and Sigma Metrics helps enhance performance assessment, improve QC strategy, and meet regulatory requirements.

null

Unique Dashboard Interface

Reduce time spent analysing data as instant identification of any QC failures over the past 7 days and alerts of product expiry are highlighted in the unique dashboard design.

null

Automated Data Import

Upload QC data directly to Acusera 24•7 via LIMS and middleware. This automated function eliminates the need for manual data entry and helps save money whilst increasing efficiency.

null

Technical Support

Expert technical support is available for users. Laboratories can access this service for troubleshooting purposes and therefore eliminates the need for on-site assistance.

Features of Acusera 24•7

  • Home Screen
  • Comprehensive Reports
  • Interactive Charts
  • Daily Data Review
  • Preview Mode
  • Results Entry
Computer screen with Acusera 24.7 the interlaboratory data management system

The fast, intelligent user interface on 24•7 enables rapid review of QC data and QC failures, reducing the time spent analysing and identifying errors.

The new and improved home screen allows users to carry out tasks such as: Creation of new tests/panels | Filtering results by analyte/ instrument/ lot number | Entering single or several QC test(s) without having to navigate away to multiple areas within the application.

Computer screen with a statistical analysis report from Acusera 24.7 the interlaboratory data management system

Specifically designed to speed up the review process, our comprehensive range of easy-to read reports include: Data Review | Exception Report | Statistical Analysis Report | Statistical Metrics Report

Customise reports to show data for a specific date range aswell as a particular test or instrument.

Computer screen with a Levey Jennings Chart from Acusera 24.7 the interlaboratory data management system

Instant access to interactive Levey-Jennings, Histogram and Performance Summary Charts as well as the ability to add events and multiple data sets to a single chart allows for swift performance monitoring and superior identification of trends across multiple instruments.

One location for all of your statistical analysis needs.

 

The enhanced data review screen on 24•7 allows users to review all QC results within a 7-day date range.

Reviewing all QC results and not just violations on a daily basis provides greater control of any potential issues occurring before they become widespread.

Preview mode on 24•7 allows users to recall the assay and instrument configurations used to create each QC test directly from the home screen.

Direct access into: Results Entry | Charts | Data Entry | QC Test Configuration | Assay Configuration for a single test, from any area in the application

Computer screen with a data review from Acusera 24.7 the interlaboratory data management system

New toggle feature allows users to set whether they are entering single or summarised results.

Reducing the number of fields for single result entry and therefore keystroke tabbing, allowing for greater ease-of-use.

Resources

We Are Here To help

To learn more about how 24•7 works as an interlaboratory data management system/ peer group reporting software. Or, to see the software in action, click below or visit our video demonstrations now.

 

Continue Reading

Acusera 24•7 FAQs

Acusera 24•7 Login

24•7 Brochure

Contact Us


Neonatal Bilirubin External Quality Assessment

The RIQAS Neonatal Bilirubin EQA programme has been designed to assess the performance of total and direct bilirubin assays with levels tailored to neonatal bilirubin testing.

  • Lyophilised for enhanced stability
  • Monthly reporting
  • Human based serum
  • Submit results and view reports online via RIQAS.net
  • Rapid turnaround of reports allows for any necessary corrective actions to be taken with minimal disruption to laboratory output

Not accredited to ISO/IEC 17043

Cat NoKit SizeFrequencyCycle StartParameters
RQ91912 x (6x3ml)MonthlyJuly2

Parameter

  • Direct Bilirubin
  • Total Bilirubin

Please note, product availability may vary country to country.


Randox International Quality Assessment Scheme (RIQAS)

RIQAS is the world’s largest External Quality Assessment scheme with more than 75,000 laboratory participants spanning over 138 countries.

Key Benefits of RIQAS

null

Cost Effective

Consolidate EQA analysis, reduce workload and costs with our comprehensive, multi-parameter programmes.

Flexible

Flexible Programme Options

Flexible programme options are available to suit all laboratory budgets. The option to register up to five instruments per programme (volume permitting) at no extra cost for comparative performance assessment

Highly Accredited

Accredited

RIQAS is accredited to ISO/IEC 17043:2010 “Conformity Assessment – General Requirements for Proficiency Testing” which is accepted by national and international accreditation bodies. Please see accreditation schedule for additional information.

null

Expansive Peer Group Database

The availability of large peer groups ensures robust data is available for a wide range of instruments and methods.

null

Rapid, User-Friendly Reports

Our rapid, user-friendly reports allow at-a-glance performance assessment. Complimentary multi-instrument, inter-laboratory and end-of-cycle reports are also available.

Commutable

Commutable Samples

A commutable sample matrix increases confidence that performance mimics that of patient samples.

null

Early Identification of Test System Errors

Frequent reporting allows early identification of test system errors, while our 72 hour report turnaround enables corrective action to be taken with minimum disruption to the lab.

null

Convenient Data Upload System

RIQAS.net is a convenient, web-based data entry system which allows participants to return results and view reports online.

null

High Quality Samples

EQA samples are manufactured to the highest quality standard and span clinically relevant levels.

RIQAS EQA Programmes

Choice & flexibility are guaranteed with our 36 programme portfolio.

Browse the programmes below

 

RIQAS EQA Reports

User-friendly, one-page per parameter reports allow for at-a-glance performance assessment.

Browse the reports below.

What Does RIQAS Provide?

The benefits of Randox Riqas as an external quality assessment

RIQAS Calendar 2024

Continue Reading

RIQAS Brochure

RIQAS Parameters

RIQAS.net

RIQAS Calendar

Contact Us


RIQAS Point of Care EQA

RIQAS Point of Care EQA Logo

Randox International Quality Assessment Scheme – Point of Care EQA

Register     /     Login

Designed to improve the quality of Point of Care Testing (POCT) in locations such as pharmacies, GP surgeries, hospital out patient departments, sports clinics, supermarkets, diagnostic/treatment and walk-in centres, RIQAS Point of Care EQA provides independent evidence of the accuracy and reliability of test results. Randox International Quality Assessment Scheme (RIQAS) is the world’s largest EQA scheme with over 55,000 participants in more than 134 countries.

Why RIQAS Point of Care?

About RIQAS Point of Care

  • How it Works

    RIQAS Point of Care - How it works
  • Tests and Analysers


    Test Role Matrix
    Lipids (Total Cholesterol & HDL Cholesterol) • Risk factors for heart disease
    • Monitoring lipid lowering therapy
    Whole Blood
    HbA1c (Glycated Haemoglobin) • Diagnosing diabetes mellitus
    • Monitoring treatment
    • Encouraging self-management
    Whole Blood
    C-Reactive Protein (CRP) • Early detection of infectious disease
    • Identifying need for antibiotic treatment
    Whole Blood
    Glucose/Ketones • Diagnose and monitor diabetes
    • Monitor for the presence of hypoglycaemia
    (low blood glucose) and hyperglycaemia (high blood glucose)
    • To determine whether excessive ketones are present in the blood, to detect diabetic ketoacidosis (DKA)
    Serum
    International Normalised Ratio (INR) • Used to measure the effect of anticoagulant
    drugs such as warfarin
    • Help diagnose a bleeding disorder; to help
    estimate the severity of liver disease
    Plasma
    Note – The RIQAS Point of Care range is constantly expanding to include new tests and analysers. Please contact us if your desired analyser or test is not currently displayed.
  • Ordering Information

    Panel Catalogue Number
    Lipids RQ9181/A
    Lipids + 1 panel RQ9181/B
    Lipids + 2 panels RQ9181/C
    Additional Sample RQ9181/D
    Glucose and Ketones RQ9188
    INR RQ9189
    Pipette Tips RQ9182
    Bulbous pipette RQ9183
  • What Participants Say

    Our unrivalled commitment to quality and service ensures high levels of customer satisfaction, this is evident from the responses to our latest customer satisfaction survey:

    “All in all a quick and efficient service”
    “Good online system”
    “Very helpful team”
    “Excellent training”
    “They are an experienced team”
    “Very satisfied with the service that we receive”
    “Very good value for money”
    “The website is great”
  • Key Cycle Dates

    RQ9181
    Distribution Month Sample Distributed Result Submission Deadline
    January 2024 8th January 17th January
    February 2024 5th February 14th February
    March 2024 4th March 13th March
    April 2024 2nd April 10th April
    May 2024 6th May 15th May
    June 2024 3rd June 12th June
    July 2024 1st  July 10th July
    August 2024 5th August 14th August
    September 2024 2nd September 11th September
    October 2024 7th October 16th October
    November 2024 4th November 13th November
    December 2024 2nd December 11th December

     

     

     

     

     

     

     

  • Importance of Quality Assurance

    Quality assurance is an essential aspect of any clinical/diagnostic testing service and is aimed at ensuring the accuracy and reliability of patients’ results. The right result allows the right clinical advice to be offered in a timely manner. Quality assurance operates at two levels:Internal Quality Control
    Internal Quality Control includes operator training/ competency assessment, analyser/ test system maintenance, and adherence to policies/ processes. Whilst some point of care analysers include inbuilt quality checks, cross-check analysis against samples with known levels provides immediate assurance and evidence that a patient’s result is safe to report.External Quality Assessment
    External Quality Assessment involves analysis of samples with unknown levels that have been distributed by an external organisation. Participants are informed how their results compare with other participants, hence providing independent evidence of performance. Increasingly, participation in an external quality assessment scheme is becoming a mandatory requirement where health and healthcare services are being provided.
    EQA provides assurance to both staff and customers that testing provides accurate and reliable results.

    Want to know more?Visit our Importance of EQA page to learn more.

Want to know more?

Contact us or download the RIQAS Point of Care catalogue to learn more.

Continue Reading

Frequently Asked Questions

RIQAS

Contact Us


RIQAS Past Panels

RIQAS (Randox International Quality Assessment Scheme) is the largest global EQA scheme with over 50,000 participants in more than 139 countries. Our range currently comprises 36 programmes and the majority of clinical testing.

What are RIQAS Past Panels?

Stemming from RIQAS, the world’s largest External Quality Assessment programme, RIQAS Past Panels* facilitate a series of QC and interlaboratory functions, including:

 

Method Validation

New Instrument Validation

Assay Evaluation

Poor Performance Troubleshooting

Staff Training

Available Panels

Available RIQAS Past Panels* include:

• Ammonia/ Ethanol
• Anti-Müllerian Hormone (AMH)
• Anti-TSH Receptor
Blood Gas
• BNP
• Cardiac
• Cardiac Plus
Cerebrospinal Fluid (CSF)
• Coagulation
• CO-Oximetry
• CYFRA 21-1
Cytokines
• ESR
• General Clinical Chemistry
• Glycated Haemoglobin (HbA1c)
• Haematology
• Human Urine
• Immunoassay
• Immunoassay Speciality 1
• Immunoassay Speciality 2
• Immunosuppressant
• Lipid
• Maternal Screening
• Microbiology (Bacterial Identification)
• Neonatal Bilirubin
Serology (Anti-SARS-CoV-2)
Serology (EBV)
• Serology (HIV/ Hepatitis)
Serology (Syphilis)
Serology (ToRCH)
Serum Indices
Specific Proteins
Sweat Testing
• Therapeutic Drugs
• Urinalysis 
• Urine Toxicology
*Product availability is dependent on RIQAS stock surplus levels.

Benefits of RIQAS Past Panels

Support Data Included

All RIQAS Past Panels are provided with an Excel document containing supporting data for the instrument and method of interest.

Multi Level Samples

RIQAS Past Panel samples span multiple levels, making them ideal for ensuring accurate instrument performance across the measuring range.

Comprehensive Reports

RIQAS Past Panels allow laboratories to receive comprehensive external QC reports even after program close.

For more information on RIQAS Past Panel availability or to take part in this EQA scheme, contact us today and speak to one of our friendly and knowledgeable sales representatives. 


Point of Care Testing (POCT) Explained

Point of Care Testing (POCT) Explained

Point of Care Testing (POCT) is the delivery of a test at the point in time at which the result will be used to make a decision and taking appropriate action resulting in an improved health outcome. It is also known as near patient, bed-side, extra-laboratory, decentralised, and ancillary testing [1]. It has been shown to reduce hospital stay time, reduce complications, and improve adherence to treatment [2].

Point of care testing is not a recent practice; many early diagnostic tests were administered at the bedside. However, analytical technology has progressed and multiple tests can be performed within minutes in a laboratory. Recently, this technology has been put into the hands of the staff near the patients [2]. There are two types of technology, benchtop analysers and hand held devices. Bench top systems are just smaller versions of laboratory analysers but some steps are automated. Hand held devices are simple in appearance but complex internally, they can manage several tasks including, adding reagents, separating cells from plasma, and reading colour or other measures.

BENEFITS OF POINT OF CARE TESTING

Results can be obtained faster, allowing for more immediate decisions meaning treatment can begin sooner. Patients can live a longer and higher quality life, helped by a reduction in the length of hospital stays.

Some benefits of POCT [2]:

•    Reduced number of clinic visits
•    Earlier discharge from hospital
•    Fewer unnecessary hospital admissions
•    Optimised drug treatment
•    More appropriate use of drugs
•    Reduced use of blood products
•    Reduced use of staff, equipment and space

Key objective

The main objective of Point of Care Testing is to generate results more quickly so that appropriate treatment can be provided, resulting in an improved patient outcome.

EFFECTIVE POINT OF CARE TESTING

Management

Accurate and reliable results can only be obtained if the patient and sample are treated correctly. Point of care testing is likely to be performed by staff with a limited technical background, so training and quality control are vital.

Outcomes

Proper analysis technique alone is not enough to ensure an accurate decision; any test will only be beneficial if the appropriate action is taken based on the result. The effectiveness of POCT is assessed in terms of the overall outcome of the patient.

WHERE DOES IT GO WRONG?

There are three phases in the POCT cycle: pre-analytical phase, analytical phase, and post-analytical phase. About 90% of quality issues are attributed to the pre-analytical and post-analytical phases [3]. These errors are mainly attributed to user error and can be caused by a number of issues including, selecting the wrong POCT device, not following manufacturer instructions, inadequate training, not adhering to appropriate QC practices, and many more.

The errors can usually be mitigated by implementing an action plan and ensuring it is executed exactly as designed, deviation from the action plan will lead to errors. Errors in POCT diagnostics can lead to misdiagnosis, improper treatment, costly follow-up procedures, and death.

Some strategies for improvement:

•    Ensure the POCT analyser is suitable for the kind of testing being undertaken
•    Ensure adequate QC to ensure your device is accurate and reliable
•    Develop a comprehensive training programme
•    Periodically carry out audits of POCT practices
THE NEED FOR QUALITY CONTROL

Internal Quality Control and External Quality Assessment is conducted to monitor the stability of the analytical measurement system and to alert the operator to a change that may lead to a medically significant error [6].

A study by Price, Smith and Bruel [8] was conducted on a number of labs over a period of time of up to 15 years. They discovered that test result performance improved with time and was associated with regular participation in External Quality Assessment (EQA) schemes and with the use of internal quality control (IQC) procedures.

Internal Quality Control

Internal Quality Control (IQC) is used to assess the day-to-day consistency of assay performance, providing quality assurance for patient results. IQC activities are among the ten most common POCT deficiencies. These may include performing and documenting quality control testing and taking the correct action for outliers [4]. This poor performance could be attributed to how IQC is viewed in POCT; users may lack appreciation of the potential for errors and may see the analyser as infallible, they likely see IQC as an additional workload as opposed to part of their testing routine.

CLSI regulations require risk assessment for each stage of patient testing alongside an implementation of a quality control plan. Below are some suggestions for how IQC should be conducted for POCT.

Conduct

IQC should be conducted when: a new lot of consumable is used; a patient result is queried; after maintenance; the device has been physically insulted. IQC should be conducted by the usual device operator so assurance can be provided for the whole testing process.

Training

ISO 22870 requires POCT users should be trained in the theory and practice of IQC [5]. Staff should be trained in every aspect of POCT including storage, preparation, frequency, documentation and basic troubleshooting.

Material

QC material for POCT should be obtained from a third party provider and not rely on material provided by the device manufacturer, the benefits of which are well documented. It should also contain analytes at clinically relevant concentrations, be provided ready-to-use, and be stable at ambient temperatures.

Results

All IQC results must be recorded with the date, time, user, decision to accept or reject, and any actions taken as appropriate. Locally assigned ranges alongside analyte-specific rules should be used to maximise error detection. An example of how IQC could be recorded and an action flowchart can be seen in Fig. A below.

Troubleshooting

There should be a protocol for required actions following a failed IQC. Any troubleshooting should be developed with knowledge of the most common errors and user capability.

Review

A monthly review should be conducted to identify persistent failures and trends.

The cost of IQC may also be a factor in resistance to IQC, however, while it is difficult to quantify, the cost of not conducting it may be greater in terms of human harm. A whitepaper is available detailing IQC in POCT (download).

Fig. A Examples of a manual IQC documentation, adapted from the Australian Government’s POCT General Practice [4]

Fig. A Examples of a manual IQC documentation, adapted from the Australian Government’s POCT General Practice  [4]. (Click to expand)

External Quality Assessment

External Quality Assessment (EQA) or Proficiency Testing (PT) involves running blind patient-like samples and comparing your results to peer results, in order to retrospectively monitor the accuracy of reporting. EQA samples should be treated as if they were a patient sample and therefore must be run by personnel who would normally use the device. This provides confidence in the reliability of patient test results. (Learn more about EQA)

Benefits of participation in an EQA programme include assessment of result accuracy, assessment over time, comparisons with instruments, methods and peers, and providing confidence in test results.

EQA for POCT is, in theory, similar to EQA in a large laboratory. There is a significant difference however, the POCT participants are usually health care professionals with little knowledge of laboratory medicine. A lack of understanding of the importance of EQA had led to a smaller percentage of sites participating than large laboratories.

A Good EQA Scheme

A good EQA scheme should offer:

•      Enables a comparison of performance between laboratories
•      Frequent reporting and rapid report turnaround time to minimise the amount of time an error can go unnoticed
•      High quality material in a format that works for you
•      Well-designed reports that allow for quick and easy troubleshooting of erroneous results at a glance
•      A sample matrix similar to a real patient sample
•      Large participant numbers to provide a large peer group to compare results to
•      A realistic range of analyte concentrations
•      Your entire range of tests in consolidated programmes, saving you time and money

“EQA should, as far as possible, cover the entire range of tests, and the entire examination process, from sample reception, preparation and analysis to interpretation and reporting.” [9]

ISO 15189

Conducting EQA in POCT

Below are some suggestions for how EQA should be conducted for POCT.

Conduct

EQA should be conducted by the operator who normally conducts patient testing to ensure the true workflow is assessed [6].

Material

EQA samples should be commutable, meaning they have the same numeric relationship between measurements procedures as is observed for a panel of patient samples (reacts the same as a real patient sample).

Report Frequency

Challenges / surveys should be frequent enough to identify systematic errors in a timely manner, affecting the fewest patient results [10].

Report Turnaround

A fast turnaround time allows test system errors to be identified sooner and necessary corrective actions to be taken immediately with minimum disruption to the lab.

Review

A regular review of past EQA results should be part of the cycle of quality.

Guidance

A POCT EQA provider should be able to provide assistance when the user is having difficulties.

Results

Individuals carrying out testing should have the correct knowledge to interpret results, choosing a scheme with easy to interpret results can help.

RANDOX POCT QUALITY CONTROL SOLUTIONS

Internal Quality Control

Randox offer a number of controls suitable for Point of Care Testing applications:

  • Acusera Blood Gas Control

    The Randox Acusera Blood Gas Quality Controls contain assayed target values for ten parameters, covering pH, pCO2, pO2, electrolytes, glucose and lactate. The material is provided in easy to open ampoules for added convenience and ease-of-use. The liquid ready-to-use nature of the control makes it ideal for use in point-of-care testing and on a wide range of blood gas instruments.

  • Acusera Liquid Cardiac Control

    The Randox Acusera Liquid Cardiac control is designed to be both convenient and easy to use. The liquid ready-to-use format makes it ideal for both clinical laboratories and point-of-care testing. Assayed, instrument specific values are provided for an impressive 8 cardiac markers including, NT-ProBNP, D-dimer and Troponin ensuring consolidation and flexibility. Furthermore, an open vial stability of 30 days for all analytes helps to keep waste and costs to a minimum.

  • Acusera Liquid HbA1c Control

    Conveniently supplied liquid ready-to-use the Liquid HbA1c control is ideally suited to both clinical laboratories and POCT helping to significantly reduce preparation time. With a stability of 30 days, waste and costs are also kept to a minimum.

  • Liquid Urine Control

    The Randox Acusera Liquid Urine quality control is designed to be both convenient and easy to use. The liquid ready-to-use format eliminates issues with pipetting and allows convenient storage at 2℃ – 8℃. Assayed instrument and method specific target values and ranges are provided for 18 commonly tested urine chemistry parameters.

External Quality Assessment

Randox offers RIQAS Point of Care, a simple EQA scheme designed for use in point of care settings. It is a single sample, single scheme programme featuring whole blood samples for authentic patient sample assessment.

Learn More
Continue Reading

RIQAS